1,2,3-Propanetricarboxylic acid, 2-hydroxy-, indium(3+)-111In salt (1:1)

Details

Stereochemistry	ACHIRAL
Molecular Formula	C6H5O7.In
Molecular Weight	300.0048
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, indium(3+)-111In salt (1:1)

Structure Search

SMILES

[111In+3].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O

InChI

InChIKey=VSEUCCPAJZHJSX-JWFOFJTQSA-K

InChI=1S/C6H8O7.In/c7-3(8)1-6(13,5(11)12)2-4(9)10;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);/q;+3/p-3/i;1-4

HIDE SMILES / InChI

Molecular Formula	In
Molecular Weight	110.905110677
Charge	3
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C6H5O7
Molecular Weight	189.0997
Charge	-3
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.drugbank.ca/drugs/DB09425 | https://www.drugs.com/mmx/indium-in-111-pentetate.html

Indium In-111 pentetate disodium is a radioactive diagnostic indicated for use in radionuclide cisternography. Decay of In-111 by electron capture allows for detection with a gamma camera for visualization of the brain and spinal column. Indium In 111 pentetate ( 111In-DTPA) is indicated as an imaging agent in cisternography to study the flow of cerebrospinal fluid (CSF) in the brain, to diagnose abnormalities in CSF circulation, to assess and help localize the site of CSF leakage, and to test the patency of or localize blocks in CSF shunts.

Approval Year

Conditions

Condition	Modality	Highest Phase	Product
hydrocephalus 9 Sources: http://www.nuclearonline.org/PI/Nycomed%20%20Indium%20DTPA%20In%20111.pdf	Diagnostic	Approved 8583	MPI INDIUM DTPA IN 111 Approved Use Unknown Launch Date 1982
syringomyelia 9 Sources: http://www.nuclearonline.org/PI/Nycomed%20%20Indium%20DTPA%20In%20111.pdf	Diagnostic	Approved 8583	MPI INDIUM DTPA IN 111 Approved Use Unknown Launch Date 1982
arachnoid cyst 9 Sources: http://www.nuclearonline.org/PI/Nycomed%20%20Indium%20DTPA%20In%20111.pdf	Diagnostic	Approved 8583	MPI INDIUM DTPA IN 111 Approved Use Unknown Launch Date 1982

Sample Use Guides

In Vivo Use Guide

The maximum recommended intrathecal dose in the average patient (70 kg) is 18.5 MBq, 500 μCi. The patient dose should be measured by a suitable radioactivity calibration system immediately prior to administration.

Route of Administration: Other

Substance Class	Chemical Created by `admin` on `Wed Apr 02 19:47:16 GMT 2025` Edited by `admin` on `Wed Apr 02 19:47:16 GMT 2025`
Record UNII	33QB3K8SC6
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

1,2,3-Propanetricarboxylic acid, 2-hydroxy-, indium(3+)-111In salt (1:1)

Preferred Name

English

INDIUM CITRATE (INDIUM-111)

Common Name

English

Code System Code Type Description

FDA UNII

33QB3K8SC6

Created by admin on Wed Apr 02 19:47:16 GMT 2025 , Edited by admin on Wed Apr 02 19:47:16 GMT 2025

PRIMARY

CAS

71895-21-1

Created by admin on Wed Apr 02 19:47:16 GMT 2025 , Edited by admin on Wed Apr 02 19:47:16 GMT 2025

PRIMARY

Related Record Type Details


					33QB3K8SC6

INDIUM IN-111 CITRATE

ACTIVE MOIETY

Comments:

TUMOR IMAGING

Amount:

Details

SMILES

InChI

DescriptionSources: https://www.drugbank.ca/drugs/DB09425 | https://www.drugs.com/mmx/indium-in-111-pentetate.html

Approval Year

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Sample Use Guides

Description
Sources: https://www.drugbank.ca/drugs/DB09425 | https://www.drugs.com/mmx/indium-in-111-pentetate.html